返回 
加入收藏
马来酸氟吡汀联合阿米替林治疗脑卒中后丘脑痛的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 马来酸氟吡汀联合阿米替林治疗脑卒中后丘脑痛的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察马来酸氟吡汀联合阿米替林治疗脑卒中后丘脑痛的疗效及安全性。方法：采用随机数字表法将我院2016年1月－2017年8月收治的70例脑卒中后丘脑痛患者随机分为对照组（34例）与观察组（36例），两组患者均给予脑卒中二级预防治疗，在此基础上，对照组患者口服盐酸阿米替林片25 mg/次，tid，观察组患者在对照组治疗基础上口服马来酸氟吡汀胶囊0.1 g/次，tid，两组疗程均为4周。评价两组患者治疗前及治疗1、2、3、4周末视觉模拟疼痛（VAS）、汉密尔顿抑郁量表（HAMD17）和汉密尔顿焦虑量表（HAMA14）评分，观察两组患者临床疗效及不良反应发生情况。结果：治疗前，两组患者VAS、HAMD17、HAMA14评分比较，差异均无统计学意义（P＞0.05）。观察组患者治疗1、2、3、4周末，对照组患者治疗2、3、4周末的VAS、HAMD17评分均显著低于治疗前，且观察组患者各治疗时段均显著低于对照组（P＜0.05或P＜0.01）；两组患者治疗2、3、4周末HAMA14评分均显著低于治疗前，且观察组患者各治疗时段均显著低于对照组（P＜0.05或P＜0.01）；观察组患者总有效率（91.67％）显著高于对照组（67.65％）（P＜0.05），两组患者不良反应发生率（11.76％ vs. 11.11％）比较，差异无统计学意义（P＞0.05）。结论：马来酸氟吡汀联合阿米替林能有效缓解脑卒中后丘脑痛症状，同时改善脑卒中后抑郁、焦虑情绪，均优于对照组且不良反应发生率与对照组相似。 |
| ABSTRACT： | OBJECTIVE： To observe the clinical efficacy and safety of flupirtine maleate combined with amitriptyline in the treatment of thalamic pain after stroke. METHODS： A total of 70 patients with thalamic pain after stroke in our hospital during Jan. 2016-Aug. 2017 were divided into control group （34 cases） and observation group （36 cases） according to random number table. Both groups received secondary prevention therapy of stroke. Based on it， control group was given Amitriptyline hydrochloride tablet 25 mg/time orally， tid. Observation group was additionally given Flupirtine maleate capsule 0.1 g/time orally， tid， on the basis of control group. Treatment course of 2 groups lasted for 4 weeks. VAS， HAMD17 and HAMA14 scores of 2 groups evaluated before treatment， after 1， 2， 3， 4 weeks of treatment Clinical efficacies and the occurrence of ADR were observed in 2 groups. RESULTS： Before treatment， there was no statistical significance in the scores of VAS， HAMD17 or HAMA14 between 2 groups （P＞0.05）. VAS score and HAMD17 score of observation group after 1， 2， 3， 4 weeks of treatment， those of control group after 2， 3 and 4 weeks of treatment were significantly lower than before treatment； the observation group was significantly lower than the control group at different time periods （P＜0.05 or P＜0.01）. HAMA14 score of 2 groups after 2， 3， 4 weeks of treatment were significantly lower than before treatment； the observation group was significantly lower than the control group at different time periods （P＜0.05 or P＜0.01）. Total efficiency rate （91.67％） of observation group were significantly higher than that （67.65％） of control group （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （11.76％ vs. 11.11％） （P＞0.05）. CONCLUSIONS： Flupirtine maleate combined with amitriptyline can effectively relieve thalamic pain after stroke， and improve post-stroke， anxiety depression， which are better than control group， and the incidence of ADR is familar to control group. |
| 期刊： | 2018年第29卷第9期 |
| 作者： | 赵艳，廖祖松，邹耀兵，潘成德，江思德 |
| AUTHORS： | ZHAO Yan，LIAO Zusong，ZOU Yaobin，PAN Chengde，JIANG Side |
| 关键字： | 马来酸氟吡汀；阿米替林；脑卒中后丘脑痛；视觉模拟疼痛评分；汉密尔顿抑郁量表评分；汉密尔顿焦虑量表评分；疗效；安全性 |
| KEYWORDS： | Flupirtine maleate； Amitriptyline； Thalamic pain after stroke； VAS； HAMD； HAMA； Therapeutic efficacy； Safety |
| 阅读数： | 822 次 |
| 本月下载数： | 45 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
